Gengagon is delivering unprecedented opportunities to fight cancer. We develop the next generation of therapeutical antibody-drug conjugates with a unique target profile and the ability to treat solid tumors, where no successful standard of care treatments is available. Our pipeline focuses on a therapeutically novel transmembrane protein class accumulating on the surface of cancer cells and tumor promoting cells within the tumor. The company is supported financially by among others, Beijer Ventures and Almi Invest.